drugset / Trial / NCT07604233
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Timeline
- Start
- 2026-11-30
- Primary completion
- 2031-06-03
- Completion
- 2033-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | — | Oral |
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Background | Cytarabine | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Idarubicin | Small molecule | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |
| Background | filgrastim | Protein / enzyme biologic | — | Other |